{"id":39042,"key":"Global_Health_Medical_Device_Compendium/Hemopurifier","title":"Global Health Medical Device Compendium/Hemopurifier","latest":{"id":1267495,"timestamp":"2026-09-10T13:39:30Z"},"content_model":"wikitext","license":{"url":"https://www.appropedia.org/Appropedia:Copyrights","title":"CC-BY-SA-4.0"},"source":"[[File:Hemopurifier.jpg|thumb]]\n\n{{GHMDC device data\n| health-topic = HIV/AIDS\n| classification = Treatment\n| scope = Clinical trial\n| made = No\n| replicated = No\n| manufacturer-location = California, United States\n}}\n\nThe Hemopurifier™ has been developed to address the treatment of drug and vaccine-resistant pathogens, including Ebola & HIV which causes AIDS.\n\n== Detailed description of the solution ==\n\nThe Hemopurifier™ is a dialysis-type medical device designed to mimic the natural immune response of clearing infectious viruses and toxins before the occurrence of cell and organ infection. Human in-vitro blood studies have documented a rapid capture of circulating HIV and gp120, a toxic surface protein known to deplete the immune T-cells required to fight off infection. If commercialized, the Hemopurifier™ would represent the first medical device enlisted as a treatment for HIV/AIDS.\n\n== Designed by ==\n\n* Design: Aethlon Medical, Inc.\n* Manufacturer Location: San Diego, California, USA\n\n== When and where it was tested/implemented ==\n\nTesting has been done in the United States since 2001. It is currently being tested in human clinical trials in India.\n\n== Funding Source ==\n\nPrivate Funding\n\n== References ==\n\n=== Peer-reviewed publication ===\n\nDuffin, R.P. & Tullis, R.H. (2002). Mathematical models that predict the complete course of HIV infection and AIDS. J. Theor. Med, 4(3), 157-166.\n\nTullis, R.H., Ambrus, J.L. & Joyce, J.A. (2001). Affinity Hemodialysis as a Treatment for AIDS. American Clinical Laboratories, Oct/Nov, 22-23.\n\nTullis, R.H., Duffin, R.P., Zech, M. & Ambrus, J.L. (2001). Affinity Hemodialysis for Antiviral Therapy. I. Removal of HIV-1 from Cell Culture Supernatants, Plasma and Blood. Therapeutic Apheresis, 6 (3), 213-220.\t\n\nTullis, R.H., Scammura, D.O. & Ambrus, J.L. (2002). Affinity Hemodialysis for Antiviral Therapy with Specific Application to HIV. J. Theor Med, 3(2002), 157-166.\n\nTullis, R.H., Duffin, R.P., Zech, M. & Ambrus, J.L. (2003). Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purification, 21(1), 58-64.\n\n=== Approval by regulatory bodies or standards boards ===\n\nAn investigational device exemption (IDE) to initiate clinical studies in the United States is pending with the Food and Drug Administration.\n\n{{Page data\n| sdg = SDG03 Good health and well-being, SDG09 Industry innovation and infrastructure\n| license = CC-BY-SA-3.0\n| language = en\n}}"}